Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30708000 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3051465 | 0.80 | TSHR (0.57) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1242879 | 0.76 | SMN1; SMN2 (0.87) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6372762 | 0.76 | — | — | |
| SCHEMBL6280604 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2198244 | 0.74 | SMN1; SMN2 (0.49) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL27756032 | 0.74 | SMN1; SMN2 (0.63) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3758733 | 0.74 | HDAC8 (0.42) | SLC6A2SLC6A4SLC6A3GAACYP17A1 | |
| SCHEMBL77244 | 0.73 | TSHR (0.58) | TSHRLMNAL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL235417 | 0.73 | TSHR (0.58) | TSHRLMNAL3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227751-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. | GALAPAGOS NV (BE) | 2022-07-21 | — | — | US | disclosed |
| EP-3378862-B1 | DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF MULTIPLE SCLEROSIS | GALAPAGOS NV (BE) | 2022-03-16 | — | — | EP | disclosed |
| CN-114127066-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-11220499-B2 | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2022-01-11 | — | — | US | disclosed |
| EP-3891148-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020114494-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-06-11 | — | — | WO | disclosed |
| US-20190002458-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. | GALAPAGOS NV (BE) | 2019-01-03 | — | — | US | disclosed |
| EP-3378862-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2018-09-26 | — | — | EP | disclosed |
| EP-2794604-B1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| US-20160244442-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. | GALAPAGOS NV (BE) | 2016-08-25 | — | — | US | disclosed |
| CN-1331689-A | 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles | HOFFMANN LA ROCHE (CH) | 2002-01-16 | — | — | CN | disclosed |
| US-6313310-B1 | JUN N-TERMINAL KINASE (JNK) ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS; RHEUMATIC ARTHRITIS AND NEURO-DEGENERATIVE DISEASE TREATMENT | HOFFMANN-LA ROCHE INC. | 2001-11-06 | — | — | US | disclosed |
| EP-1149092-A2 | 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| EP-0900217-A4 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000035906-A2 | 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
| US-6069159-A | USEFUL AS STIMULANTS OF THE COGNITIVE FUNCTION OF THE FOREBRAIN AND HIPPOCAMPUS OF MAMMALS | ELI LILLY AND COMPANY (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0900217-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| EP-0888355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997040042-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997034899-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227751-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. | GPR84, GPR88, GPR65 | SMN1; SMN2 4089/4885CFTR 168/4885SLC6A2 4271/4885 |
| US-20190002458-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. | GPR84, GPR88, GPR65 | SMN1; SMN2 4089/4885CFTR 168/4885SLC6A2 4271/4885 |
| US-20160244442-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. | GPR84, GPR88, GPR65 | SMN1; SMN2 4089/4885CFTR 168/4885SLC6A2 4271/4885 |
| US-11220499-B2 | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GPR84, GPR88, GPR65 | SMN1; SMN2 4136/4885CFTR 172/4885SLC6A2 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.